Increased Risk of Infusion Site Reactions with Fosaprepitant in Patients Receiving Anthracyclines

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Anticancer Research, researchers have found that fosaprepitant, the intravenous formulation of the NK1 receptor antagonist aprepitant for the treatment of chemotherapy-induced nausea and vomiting, is associated with an increased risk of infusion site reactions in patients receiving anthracycline-based chemotherapy regimens compared with those receiving cisplatin-based regimens.

For the study, researchers sought to investigate the incidence of infusion site adverse effects in patients receiving different chemotherapy regimens. They retrospectively identified 267 patients who received either cisplatin- or anthracycline-based regimens.

Results showed that 41.7% of patients who received fosaprepitant experienced infusion site reactions compared with 10.9% of those who received aprepitant to prevent nausea and vomiting. Analyses showed no association between fosaprepitant and an elevated risk of infusion site adverse events in those receiving cisplatin-based regimens, but there was an assocation between the drug and an increased risk of infusion site adverse events among those who were administered anthracycline-based regimens (OR = 12.95; 95% CI: 5.74 - 29.20; P = 0.001).

The IV Emend prescribing information notes that infusion site reactions were experienced in 3% of patients that received fosaprepitant during clinical studies.

Non-NK1 receptor antagonists Effective Against Chemotherapy-induced Nausea and Vomiting
Fosaprepitant associated with increased risk of infusion site reactions in patients receiving anthracycline-based chemotherapy.
Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs